Nasdaq:MDGL
MADRIGAL PHARMACEUTICALS, INC.
MADRIGAL PHARMACEUTICALS is a biopharmaceutical innovator developing next-generation therapies with a strong cash position despite recent net losses.
Key Metrics
Investment Thesis
Bull Case
MDGL offers exposure to high-potential biopharmaceutical assets with a strong cash reserve of $198.7M providing a runway for development without immediate need for dilutive financing. The recent revenue growth from $180.1M in 2024 to $958.4M in 2025 suggests successful commercialization or licensing milestones that could accelerate toward profitability. Investors may view the current losses as a strategic cost of bringing transformative therapies to market rather than an operational failure.
Bear Case
The persistent net losses over the last three years, totaling nearly $1B combined from 2022 to 2024, demonstrate a lack of sustainable profitability that investors must scrutinize closely. With accounts receivable significantly higher than cash on hand ($134.5M vs $198.7M), there is a risk of collection issues or revenue recognition timing problems affecting liquidity. The company's reliance on external financing ($256.0M inflow) to cover operational deficits creates dependency risks if future funding markets tighten.
About MADRIGAL PHARMACEUTICALS, INC.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) operates within the biopharmaceutical sector, focusing on the development and commercialization of innovative therapies. The company serves markets requiring specialized pharmaceutical solutions, leveraging its pipeline to address significant unmet medical needs. With a substantial focus on R&D and strategic partnerships, MDGL aims to generate revenue from its proprietary drug candidates.
Analysis
Management Discussion
Despite a revenue increase to $958.4M in 2025 from the prior year, the company reported a net loss of $-288.3M and an operating profit of $-300.1M, highlighting ongoing high burn rates typical of biotech development. Cash flow from operations was negative at $-189.6M, partially offset by financing activities bringing in $256.0M, resulting in a net cash increase to $203.8M. The disparity between gross profit ($958.4M) and operating expenses ($1.26B) underscores the heavy investment required in general and administrative functions relative to current product revenue.
Industry Overview
The biopharmaceutical industry is characterized by high R&D expenditures, long development cycles, and significant regulatory hurdles before products reach the market. Companies in this sector often operate with negative earnings while building pipelines that can yield blockbuster revenues upon approval. Market dynamics favor firms with strong intellectual property portfolios and diversified revenue streams from partnerships to mitigate the risk of single-product failure.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $180.1M | $958.4M |
| Cost of Revenue | $0 | $0 | $6.2M | $0 |
| Gross Profit | $0 | $0 | $173.9M | $958.4M |
| Operating Expenses | $293.6M | $380.5M | $671.8M | $1.26B |
| Operating Income | $-293.6M | $-380.5M | $-497.9M | $-300.1M |
| G&A | $48.1M | $108.1M | $435.1M | $813.8M |
| Stock-Based Comp | $31.6M | $49.7M | $79.9M | $98.1M |
| D&A | $467.0K | $527.0K | $1.1M | $1.5M |
| Other OpEx | $245.4M | $272.4M | $236.7M | $444.7M |
| Non-Operating Income | $0 | $0 | $0 | $141.6M |
| Interest Expense | $4.0M | $12.7M | — | — |
| Interest Income | $2.2M | $19.6M | $46.7M | $37.4M |
| Pre-Tax Income | $-293.6M | $-380.5M | $-497.9M | $-158.5M |
| Income Tax | $0 | $0 | $0 | $0 |
| Continuing Ops | $-293.6M | $-380.5M | $-497.9M | $-158.5M |
| Discontinued Ops | $0 | $0 | $0 | $-129.8M |
| Net Income | $-295.4M | $-373.6M | $-465.9M | $-288.3M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-295.4M | $-373.6M | $-465.9M | $-288.3M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $361.4M | $637.3M | $1.03B | $1.25B |
| Cash & Equivalents | $331.5M | $99.9M | $100.0M | $198.7M |
| Accounts Receivable | — | — | $53.8M | $134.5M |
| Inventory | — | — | $34.1M | $74.8M |
| Prepaid Expenses | $2.6M | $3.1M | $13.8M | $47.8M |
| Other Current Assets | $27.2M | $534.2M | $831.2M | $790.0M |
| Long-Term Assets | $1.2M | $3.3M | $9.3M | $13.8M |
| PP&E (Net) | $601.0K | $1.6M | $2.2M | $1.5M |
| Operating Leases | $602.0K | $1.7M | $2.4M | $4.9M |
| Other LT Assets | $0 | $0 | $4.7M | $7.4M |
| Total Assets | $362.6M | $640.5M | $1.04B | $1.26B |
| Current Liabilities | $115.9M | $118.5M | $169.3M | $310.3M |
| Accounts Payable | $23.8M | $28.0M | $43.6M | $48.9M |
| Current Leases | $602.0K | $527.0K | $983.0K | $1.0M |
| Other Current Liab | $0 | $0 | $0 | $0 |
| Long-Term Liabilities | $49.3M | $116.7M | $118.6M | $346.6M |
| Long-Term Debt | $49.3M | $115.5M | $117.6M | $339.9M |
| LT Operating Leases | $0 | $1.2M | $1.0M | $6.7M |
| Other LT Liab | $0 | $0 | $0 | $0 |
| Total Liabilities | $165.2M | $235.2M | $287.9M | $656.9M |
| Shareholders' Equity | $197.4M | $405.3M | $754.4M | $602.7M |
| Retained Earnings | $-962.7M | $-1.34B | $-1.80B | $-2.09B |
| AOCI | $-32.0K | $468.0K | $468.0K | $873.0K |
| Total L&E | $362.6M | $640.5M | $1.04B | $1.26B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-295.4M | $-373.6M | $-465.9M | $-288.3M |
| Non-Cash Adjustments | $30.4M | $46.1M | $-138.5M | $-190.1M |
| Working Capital Changes | $40.1M | $3.3M | $148.8M | $288.8M |
| Cash from Operations | $-224.9M | $-324.2M | $-455.6M | $-189.6M |
| Capital Expenditures | $217.0K | $1.5M | $1.5M | $467.0K |
| Cash from Investing | $206.7M | $-502.5M | $-274.4M | $32.3M |
| Cash from Financing | $313.5M | $595.1M | $735.1M | $256.0M |
| FX Effect | $0 | $0 | $0 | $13.0K |
| Net Change in Cash | $295.3M | $-231.6M | $5.1M | $98.8M |
| Beginning Cash | $36.3M | $331.5M | $99.9M | $105.0M |
| Ending Cash | $331.5M | $99.9M | $105.0M | $203.8M |
Frequently Asked Questions
How does MADRIGAL PHARMACEUTICALS, INC. make money?
The company's revenue streams are primarily derived from the commercialization of its proprietary pharmaceutical pipeline and strategic licensing agreements. Significant portions of operating expenses are allocated to general administration, R&D activities, and cost of goods sold for manufacturing finished drugs. The financials indicate a heavy investment in long-term assets related to intellectual property and operational capabilities.
What are the main risks for MDGL?
The company faces significant net losses of $288.3M in 2025, raising concerns about its path to profitability and cash burn rate. Regulatory approval uncertainties for new drug candidates could delay or prevent anticipated revenue recognition from the pipeline. High levels of accounts payable ($48.9M) and accrued expenses ($260.4M) suggest potential liquidity pressures or pending contractual obligations. The substantial retained earnings deficit of $-2.09B indicates historical challenges in sustaining profitable operations.
What is MDGL's competitive advantage?
The company holds a robust portfolio of proprietary drug candidates that provide exclusive market access and potential high-margin revenue streams. MADRIGAL maintains a strong balance sheet with nearly $200 million in cash and equivalents, offering flexibility for R&D expansion or acquisitions. The firm's strategic partnerships likely include milestone payments and royalty structures that supplement commercial sales.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.